RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

A+C, Yes, most likely between now and the R/S for the CX-1739 results (imo), and then the anticipation over the Dronabinol results coming not long thereafter will help keep interest in the stock post R/S so the share price doesn't crumble too much.

That's the recipe for a successful R/S -- clinical progress plus buzz/anticipation of more to come. As things stand now, I don't know if they've created enough awareness of the upcoming CX-1739 RD results, and not webcasting the last presentation doesn't help.

Imo they also need to put out a few press releases with info on how CX-1739 could have prevented the type of RD/respiratory depression associated with the deaths of Michael Jackson, Joan Rivers, Prince, etc. Ampakines not only prevent and reverse opioid induced RD, but also RD due to propofol, barbiturates, and benzodiazepines. It works so well because the area of the brain that controls respiratory drive (pre-Botzinger Complex) is jam packed with AMPA receptors.

The post R/S price will likely be in the 7-10 area (325 to 1 R/S), so there's considerable room for it to drop and possibly attract short sellers. Therefore RSPI should pull out all the stops to get a good level of buzz going. So far that effort has been underwhelming imo, but there's still time for some showmanship. Not looking for hype, just some well crafted publicity.